immunotherapy

IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:…

4 weeks ago

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

OXFORD, United Kingdom, May 13, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel…

4 weeks ago

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference

NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…

4 weeks ago

Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives

Supports expansion of Tevogen’s ExacTcell™ platform toward additional clinical trialsBolsters a financial path to positive cashflow and minimizes dilution WARREN, N.J.,…

1 month ago

Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates

WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology…

1 month ago

Poolbeg Pharma PLC Announces Annual Report & AGM Notice

LONDON, UK / ACCESSWIRE / May 9, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on…

1 month ago

Poolbeg Pharma PLC Announces Annual Report & AGM Notice

LONDON, UK / ACCESSWIRE / May 9, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on…

1 month ago

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after…

1 month ago

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after…

1 month ago

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

– Accomplished industry veteran brings deep strategic and operational expertiseDENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating…

1 month ago